Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Big Pharma
Alisa Harbin was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.   17 August 2018
Americas
Robert DeBerardine was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.   16 August 2018
Americas
Padmanabh Bhatt was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.   15 August 2018
article
Roy Waldron was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.   14 August 2018
Big Pharma
Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate.   14 August 2018
article
Elaine Waller was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.   13 August 2018
Americas
Lorie Ann Morgan was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.   10 August 2018
Europe
Emma Walmsley was selected in the LSIPR 50 2018 publication for​ ​her influence on the life sciences industry. She featured in the business and innovation section, as LSIPR reports.   9 August 2018
Europe
Antoine Petit was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.   8 August 2018
Americas
If enacted by Congress, the proposed amendment to the Hatch-Waxman Act would spell trouble for generic pharmaceutical companies seeking to take on brand competitors in patent litigation, says Janine Carlan of Arent Fox.   8 August 2018